Kahuna Workforce Solutions has officially deployed its platform at Memorial Hermann Health System. Photo via RSM Design

More than 14,000 nurses at one of the largest nonprofit health care providers in Texas have access to a new skills and competency management software.

Kahuna Workforce Solutions has officially deployed its platform at Memorial Hermann Health System, consisting of 17 hospitals and more than 250 care delivery sites. The platform will streamline onboarding processes and increase transparency and accessibility for staff.

“Kahuna will enhance our clinical competency experience and fully aligns with our nursing strategy to optimize our processes, prioritize innovation and safety, and excel as a top provider of care and clinical advancement for clinicians,” Bryan Sisk, senior vice president and chief nursing executive for Memorial Hermann, says in a news release.

“Memorial Hermann is committed to the Houston community and helping to develop the next generation of nurses,” Sisk continues. “The Kahuna platform will help improve the transparency, autonomy and efficiency of our competency management and development processes for our nurses to better support them in their roles, while also ensuring we provide high-quality care for our patients.”

The rollout comes six months after the software-as-a-service company raised a $21 million series B round of funding.

“We are thrilled to work with Memorial Hermann as they enrich all aspects of their clinical competency management practices with Kahuna’s skills management software,” adds Jai Shah, CEO of Kahuna Workforce Solutions. “This collaboration unites two Houston-based organizations and demonstrates a joint commitment to enhancing the standard of health care through digitized competency management in our Houston community and far beyond.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”